The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs
Open accessAbstract
Background: Exosomes or secreted bi-lipid vesicles from human ESC-derived mesenchymal stem cells (hESC-MSCs) have been shown to reduce myocardial ischemia/reperfusion injury in animal models. However, as hESC-MSCs are not infinitely expansible, large scale production of these exosomes would require replenishment of hESC-MSC through derivation from hESCs and incur recurring costs for testing and validation of each new batch. Our aim was therefore to investigate if MYC immortalization of hESC-MSC would circumvent this constraint without compromising the production of therapeutically efficacious exosomes. Methods: The hESC-MSCs were transfected by lentivirus carrying a MYC gene. The transformed cells were analyzed for MYC transgene integration, transcript and protein levels, and surface markers, rate of cell cycling, telomerase activity, karyotype, genome-wide gene expression and differentiation potential. The exosomes were isolated by HPLC fractionation and tested in a mouse model of myocardial ischemia/reperfusion injury, and infarct sizes were further assessed by using Evans' blue dye injection and TTC staining. Results: MYC-transformed MSCs largely resembled the parental hESC-MSCs with major differences being reduced plastic adherence, faster growth, failure to senesce, increased MYC protein expression, and loss of in vitro adipogenic potential that technically rendered the transformed cells as non-MSCs. Unexpectedly, exosomes from MYC-transformed MSCs were able to reduce relative infarct size in a mouse model of myocardial ischemia/reperfusion injury indicating that the capacity for producing therapeutic exosomes was preserved. Conclusion: Our results demonstrated that MYC transformation is a practical strategy in ensuring an infinite supply of cells for the production of exosomes in the milligram range as either therapeutic agents or delivery vehicles. In addition, the increased proliferative rate by MYC transformation reduces the time for cell production and thereby reduces production costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Mesenchymal stem cells as trophic mediators
Caplan, A. I., & Dennis, J. E. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20886 · Cited by 2,992
PANTHER: A Library of Protein Families and Subfamilies Indexed by Function
Thomas, P. D., Campbell, M. J., Kejariwal, A., Mi, H., Karlak, B., Daverman, R., Diemer, K., Muruganujan, A., & Narechania, A. (2003) · Genome Research · doi:10.1101/gr.772403 · Cited by 2,944
Pfeffer, M. A., & Braunwald, E. (1990) · Circulation · doi:10.1161/01.cir.81.4.1161 · Cited by 2,877
Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury
Lai, R. C., Arslan, F., Lee, M. M., Sze, N. S. K., Choo, A., Chen, T. S., Salto-Tellez, M., Timmers, L., Lee, C. N., El Oakley, R. M., et al. (2010) · Stem Cell Research · doi:10.1016/j.scr.2009.12.003 · Cited by 2,215
Self-citationGnecchi, M., He, H., Liang, O. D., Melo, L. G., Morello, F., Mu, H., Noiseux, N., Zhang, L., Pratt, R. E., Ingwall, J. S., et al. (2005) · Nature Medicine · doi:10.1038/nm0405-367 · Cited by 1,677 · cited 2×
“In recent years, MSC transplantations have demonstrated therapeutic efficacy in treating different diseases but the underlying mechanism has been controversial [2-9].”
BackgroundSun, D., Zhuang, X., Xiang, X., Liu, Y., Zhang, S., Liu, C., Barnes, S., Grizzle, W., Miller, D., & Zhang, H.-G. (2010) · Molecular Therapy · doi:10.1038/mt.2010.105 · Cited by 1,572
Mesenchymal Stem Cells and Their Potential as Cardiac Therapeutics
Pittenger, M. F., & Martin, B. J. (2004) · Circulation Research · doi:10.1161/01.res.0000135902.99383.6f · Cited by 1,429
Kinnaird, T., Stabile, E., Burnett, M. S., Shou, M., Lee, C. W., Barr, S., Fuchs, S., & Epstein, S. E. (2004) · Circulation · doi:10.1161/01.cir.0000124062.31102.57 · Cited by 1,305
Self-citationMonolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction
Miyahara, Y., Nagaya, N., Kataoka, M., Yanagawa, B., Tanaka, K., Hao, H., Ishino, K., Ishida, H., Shimizu, T., Kangawa, K., et al. (2006) · Nature Medicine · doi:10.1038/nm1391 · Cited by 1,193
Tögel, F., Hu, Z., Weiss, K., Isaac, J., Lange, C., & Westenfelder, C. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00007.2005 · Cited by 1,178
Gnecchi, M., He, H., Noiseux, N., Liang, O. D., Zhang, L., Morello, F., Mu, H., Melo, L. G., Pratt, R. E., Ingwall, J. S., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-5211com · Cited by 1,157
Adult Bone Marrow–Derived Cells for Cardiac Repair: A Systematic Review and Meta-analysis
Abdel-Latif, A. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.10.989 · Cited by 880
Ventricular Remodeling after Myocardial Infarction
Mitchell, G. F., Lamas, G. A., & Pfeffer, M. A. (1993) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-2946-0_25 · Cited by 755
Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics
Kitamura, T., Koshino, Y., Shibata, F., Oki, T., Nakajima, H., Nosaka, T., & Kumagai, H. (2003) · Experimental Hematology · doi:10.1016/j.exphem.2003.07.005 · Cited by 737
Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs
Chen, T. S., Lai, R. C., Lee, M. M., Choo, A. B. H., Lee, C. N., & Lim, S. K. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp857 · Cited by 658
Self-citationReduction of myocardial infarct size by human mesenchymal stem cell conditioned medium
Timmers, L., Lim, S. K., Arslan, F., Armstrong, J. S., Hoefer, I. E., Doevendans, P. A., Piek, J. J., El Oakley, R. M., Choo, A., Lee, C. N., et al. (2008) · Stem Cell Research · doi:10.1016/j.scr.2008.02.002 · Cited by 617
Self-citationNakagami, H., Maeda, K., Morishita, R., Iguchi, S., Nishikawa, T., Takami, Y., Kikuchi, Y., Saito, Y., Tamai, K., Ogihara, T., et al. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000190701.92007.6d · Cited by 577
Thomas, P. D., Kejariwal, A., Guo, N., Mi, H., Campbell, M. J., Muruganujan, A., & Lazareva-Ulitsky, B. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl229 · Cited by 499
Mesenchymal stem cells: progress toward promise
Le Blanc, K., & Pittenger, M. F. (2005) · Cytotherapy · doi:10.1016/s1465-3249(05)70787-8 · Cited by 389
Mayer, H., Bertram, H., Lindenmaier, W., Korff, T., Weber, H., & Weich, H. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20462 · Cited by 324
Derivation of Clinically Compliant MSCs from CD105+, CD24− Differentiated Human ESCs
Lian, Q., Lye, E., Suan Yeo, K., Khia Way Tan, E., Salto-Tellez, M., Liu, T. M., Palanisamy, N., El Oakley, R. M., Lee, E. H., Lim, B., et al. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0420 · Cited by 317
Self-citationElucidating the Secretion Proteome of Human Embryonic Stem Cell-derived Mesenchymal Stem Cells
Sze, S. K., de Kleijn, D. P. V., Lai, R. C., Khia Way Tan, E., Zhao, H., Yeo, K. S., Low, T. Y., Lian, Q., Lee, C. N., Mitchell, W., et al. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m600393-mcp200 · Cited by 265
Self-citationCytokine interactions in mesenchymal stem cells from cord blood
LIU, C., & HWANG, S. (2005) · Cytokine · doi:10.1016/j.cyto.2005.11.003 · Cited by 211
Mesenchymal Stem Cells and the Treatment of Cardiac Disease
Minguell, J. J., & Erices, A. A. (2006) · Experimental Biology and Medicine · doi:10.1177/153537020623100105 · Cited by 170
Lai, R. C., Arslan, F., Tan, S. S., Tan, B., Choo, A. B. H., Lee, M. M., Chen, T. S., Teh, B. J., Eng, J. K. L., Sidik, H., et al. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.12.021 · Cited by 156
Self-citationLeedham, S. J., Brittan, M., McDonald, S. A. C., & Wright, N. A. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00333.x · Cited by 145
Cheng, L., Qasba, P., Vanguri, P., & Thiede, M. A. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200007)184:1<58::aid-jcp6>3.0.co;2-b · Cited by 137
Multilineage Potential of Stable Human Mesenchymal Stem Cell Line Derived from Fetal Marrow
Nagai, A., Kim, W. K., Lee, H. J., Jeong, H., Kim, K. S., Hong, S. H., Park, I. H., & Kim, S. U. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001272 · Cited by 117
Mesenchymal Stem Cells for Cardiac Regenerative Therapy
Schuleri, K. H., Boyle, A., & Hare, J. M. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-68976-8_9 · Cited by 104
Overstraeten‐Schlögel, N. V., Beguin, Y. P., & Gothot, A. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00633.x · Cited by 94
Therapeutic use of stem and endothelial progenitor cells in acute renal injury: ça ira
Patschan, D., Plotkin, M. D., & Goligorsky, M. S. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.10.013 · Cited by 72
Lentiviral vectors in clinical trials: Current status.
D’Costa, J., Mansfield, S. G., & Humeau, L. M. P. F. (2009) · PubMed · Cited by 60
Opportunities and challenges for mesenchymal stem cell-mediated heart repair
Atsma, D. E., Fibbe, W. E., & Rabelink, T. J. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282f0dd1f · Cited by 55
Prepare Cells to Repair the Heart: Mesenchymal Stem Cells for the Treatment of Heart Failure
Ohnishi, S., & Nagaya, N. (2007) · American Journal of Nephrology · doi:10.1159/000102000 · Cited by 38
Advances in Cell-Based Therapy for Structural Heart Disease
Mazhari, R., & Hare, J. M. (2007) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2007.03.004 · Cited by 37
Que, J., Lian, Q., Oakley, R. M. E., Lim, B., & Lim, S. K. (2007) · Journal of Molecular Signaling · doi:10.1186/1750-2187-2-9 · Cited by 24
Self-citationOptimizing adult mesenchymal stem cells for heart repair
Behfar, A., & Terzic, A. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.11.003 · Cited by 21
Cited by
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099
“including mode of immortalization [9], are advisable for all cell studies.”
Self-citationExtracellular vesicles: biology and emerging therapeutic opportunities
EL Andaloussi, S., Mäger, I., Breakefield, X. O., & Wood, M. J. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3978 · Cited by 3,571
Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper
Lener, T., Gimona, M., Aigner, L., Börger, V., Buzas, E., Camussi, G., Chaput, N., Chatterjee, D., Court, F. A., del Portillo, H. A., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.30087 · Cited by 1,491
Self-citationMesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine
Vizoso, F., Eiro, N., Cid, S., Schneider, J., & Perez-Fernandez, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091852 · Cited by 1,363
Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications
Rani, S., Ryan, A. E., Griffin, M. D., & Ritter, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.44 · Cited by 1,227
Metadata
- Authors
- Chen, T. S., Arslan, F., Yin, Y., Tan, S. S., Lai, R. C., Choo, A. B. H., Padmanabhan, J., Lee, C. N., de Kleijn, D. P., & Lim, S. K.
- Venue
- Journal of Translational Medicine
- Published
- 2011-04-25
- Volume
- 9
- Issue
- 1
- Pages
- 47-47
- ISSN
- 1479-5876 (ISSN-L)
- OpenAlex
- W2106583271
- Cited by
- 397
- References
- 38
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.